Cost-Utility Analysis of Erenumab Compared to Topiramate for Preventive Therapy of Migraine in Iran.

ABSTRACT:

Background

Migraine is a prevalent, chronic neurovascular disorder that incurs significant indirect costs due to productivity loss. Preventive therapy is an effective way to alleviate the societal and healthcare burden of migraine. Approximately 14% of both the global and Iranian populations are affected by migraine, which has substantial economic implications.

Objectives

To determine the cost-effectiveness of Erenumab compared to Topiramate for migraine treatment in Iran.

Methods

A three-state Markov model was used to evaluate the cost-effectiveness of Erenumab. The model considered both direct and indirect costs from a societal perspective. The incremental cost-effectiveness ratio (ICER) was calculated by determining the cost per quality-adjusted life year (QALY) ga

SUBMITTER: Mollaee H 

PROVIDER: S-EPMC11742578 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature